San Francisco startup Framework Therapeutics is likewise working on an oral, as soon as-every day GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June every time a mid-stage review showed common weight loss of close to six% and it ideas to start out another mid-phase trial in direction of the tip of this yr—that f